Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Bromhexine  COVID-19 treatment studies for Bromhexine  C19 studies: Bromhexine  Bromhexine   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
 
    
  
Bromhexine for COVID-19
6 studies from 72 scientists
684 patients in 3 countries
Statistically significant improvement for ventilation and ICU.
79%, 12% improvement for early and late treatment CI [28-94%], [-20-36%]
Bromhexine may be less effective for omicron due to the entry process moving towards TMPRSS2-independent fusion.
COVID-19 Bromhexine studies. Dec 2022. c19early.org/b
0 0.5 1 1.5+ All studies 50% Mortality 77% Hospitalization 14% Recovery 43% Cases 62% Viral clearance 44% RCTs 50% RCT mortality 77% Prophylaxis 65% Early 79% Late 12% Favorsbromhexine Favorscontrol
Bromhexine COVID-19 studies. Bromhexine may be less effective for omicron due to the entry process moving towards TMPRSS2-independent fusion [Peacock, Willett]. Submit updates/corrections.
Dec 2
Covid Analysis (Preprint) (meta analysis) Bromhexine for COVID-19: real-time meta analysis of 6 studies
Statistically significant improvements are seen for ventilation and ICU admission. 3 studies from 3 independent teams in 2 different countries show statistically significant improvements in isolation (not for the most serious outcome). ..
Jan 3
Peacock et al., bioRxiv, doi:10.1101/2021.12.31.474653 (Preprint) (In Vitro) The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry
In Vitro study showing that omicron can efficiently enter cells via the endosomal route, independent of TMPRSS2.
Jan 3
Willett et al., medRxiv, doi:10.1101/2022.01.03.21268111 (Preprint) (In Vitro) The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism
In Vitro study showing that the entry process for omicron has moved towards TMPRSS2-independent fusion, indicating that TMPRSS2 inhibitors may be less effective for omicron.
Dec 20
2021
Tolouian et al., SSRN, doi:10.2139/ssrn.3989 (Preprint) Bromhexine, for Post Exposure COVID-19 Prophylaxis: A Randomized, Double-Blind, Placebo Control Trial
70% lower hospitalization [p=0.15], 53% fewer symptomatic cases [p=0.007], and 50% fewer cases [p=0.03]. PEP RCT with 372 close contacts of COVID+ patients, 187 treated with bromhexine, showing significantly lower cases with treatment. IRCT20120703010178N22.
Apr 30
2021
Sgrignani et al., Frontiers in Molecular Biosciences, doi:10.3389/fmolb.2021.666626 Computational Identification of a Putative Allosteric Binding Pocket in TMPRSS2
In Silico study of TMPRSS2 inhibition by camostat, nafamostat, and bromhexine, suggesting allosteric binding for bromhexine, compared to camostat and nafamostat which bind to the active site of TMPRSS2 forming covalent adducts.
Mar 15
2021
Tolouian et al., J. Investig. Med., doi:10.1136/jim-2020-001747 Effect of bromhexine in hospitalized patients with COVID-19
76% lower mortality [p=0.43], 76% better improvement [p=0.43], and 75% worse viral clearance [p=0.02]. Small RCT with 100 patients, 48 with bromhexine added to SOC, showing slower viral- conversion but lower mortality and greater clinical improvement with bromhexine (not statistically significant with few deaths and very high recovery). Th..
Mar 8
2021
Mikhaylov et al., medRxiv, doi:10.1101/2021.03.03.21252855 (Preprint) Bromhexine Hydrochloride Prophylaxis of COVID-19 for Medical Personnel: A Randomized Open-Label Study
91% fewer symptomatic cases [p=0.05] and 71% improved viral clearance [p=0.14]. Small prophylaxis RCT with 25 treatment and 25 control health care worker, showing lower PCR+, symptomatic cases, and hospitalization with treatment, although not statistically significant with the small sample size.
Jan 31
2021
Carpinteiro et al., Journal of Biological Chemistry, doi:10.1016/j.jbc.2021.100701 (In Vitro) Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells
In Vitro study showing that ambroxol (a metabolite of bromhexine) inhibits SARS-CoV-2 infection.
Dec 31
2020
Al-Kuraishy et al., Current Medical and Drug Research (Review) (Preprint) The potential role of Bromhexine in the management of COVID-19: Decipher and a real game-changer
Review article noting that bromhexine is a TMPRSS2 inhibitor with greater effect in lung tissue and attenuates the entry and proliferation of SARS‐CoV‐2.
Dec 3
2020
Mareev et al., Кардиология, doi:10.18087/cardio.2020.11.n1440 Results of Open-Label non-Randomized Comparative Clinical Trial: “BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT)
11% improved recovery [p=0.47], 39% higher hospital discharge [p=0.02], 8% shorter hospitalization [p=0.35], and 87% improved viral clearance [p=0.08]. Prospective 103 PCR+ patients in Russia, 33 treated with bromexhine+spironolactone, showing lower PCR+ at day 10 or hospitalization >10 days with treatment. Bromhexine 8mg 4 times daily, spironolactone 25-50 mg/day for 10 days.
Sep 3
2020
Li et al., Clinical and Translational Science, doi:10.1111/cts.12881 Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID‐19: An Open‐Label Randomized Controlled Pilot Study
75% higher hospital discharge [p=0.11] and 3% slower recovery. Tiny RCT with 12 bromhexine and 6 control patients showing non-statistically significant improvements in chest CT, need for oxygen therapy, and discharge rate within 20 days. Authors recommend a larger scale trial.
Jul 19
2020
Ansarin et al., Bioimpacts, doi:10.34172/bi.2020.27 Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial
91% lower mortality [p=0.05], 89% lower ventilation [p=0.01], and 82% lower ICU admission [p=0.01]. RCT with 39 bromhexine and 39 control patients showing lower mortality, intubation, and ICU admission with treatment. The treatment group received bromhexine hydrochloride 8 mg three times a day for two weeks. All patients received SOC in..
May 26
2020
Depfenhart et al., Internal and Emergency Medicine, doi:10.1007/s11739-020-02383-3 (Theory) Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy?
Proposal to use bromhexine to inhibit TMPRSS2-specific viral entry for prophylaxis and treatment of COVID-19.
Apr 30
2020
Habtemariam et al., Pharmacol. Res., doi:10.1016/j.phrs.2020.104853 (Theory) Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2
Note on the potential use of bromhexine hydrochloride for prophylaxis of SARS-CoV-2, based on the role of TMPRSS2 in SARS-CoV-2 infection, and the TMPRSS2 inhibition of bromhexine hydrochloride.
Apr 22
2020
Maggio et al., Pharmacol Res., doi:10.1016/j.phrs.2020.104837 (Review) Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection
Proposal to use bromhexine for prophylaxis and treatment of COVID-19 based on TMPRSS2 inhibition, widespread clinical use, and supporting pharmacokinetic and safety data.
Mar 5
2020
Hoffman et al., Cell, doi:10.1016/j.cell.2020.02.052 (In Vitro) SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibito
In Vitro study showing that SARS-CoV-2 uses ACE2 for entry and TMPRSS2 for S protein priming, and that TMPRSS2 inhibitor camostat blocked entry and may be an effective treaetment.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit